secwatch.observer — SEC 8-K summary
======================================

Issuer:     Coya Therapeutics, Inc. (COYA)
CIK:        0001835022
Form:       8-K
Filed at:   2025-05-13T23:59:59+00:00
Accession:  0000950170-25-069819
Event type: earnings
Sentiment:  neutral
Materiality: 0.70
Item codes: 2.02, 7.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Coya Therapeutics Q1 net loss $7.3M; pipeline milestones for COYA 302 detailed
------------------------------------------------------------------------------

- Net loss of $7.3M in Q1 2025 vs $5.1M in Q1 2024; R&D expense rose to $5.2M from $3.1M.
- Cash and cash equivalents $35.5M as of March 31, 2025.
- Positive interim results from investigator-initiated trial of LD IL-2 + CTLA4-Ig in Frontotemporal Dementia.
- Expects IND submission for COYA 302 in ALS in Q2 2025; $8.4M milestone from DRL due upon first dosing.
- Plans to file IND for COYA 302 in FTD by end of 2025.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1835022/000095017025069819/0000950170-25-069819-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1835022/000095017025069819/coya-20250513.htm
  HTML page:      https://secwatch.observer/filing/0000950170-25-069819

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer